CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. (CASI) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CASI · as of Sep 30, 2025
Ownership Breakdown
21
Institutional Holders
▼ 2 vs Q2
$4.33M
Total Inst. Value
▲ $1.68M vs Q2
15.49M
Shares Outstanding
freeFloat 22.06%
2.61M
13F Shares Held
▲ 361,675 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CASI largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VR ADVISER, LLC biological products, (no diagnostic substances) | 987.3K | 6.37% | 6.37% | $1.64B | Nov 14, 2025 | — held |
FORESITE CAPITAL MANAGEMENT VI LLC biological products, (no diagnostic substances) | 980.0K | 6.32% | 6.32% | $1.63B | Nov 14, 2025 | ▲ 192.8K |
BANK OF AMERICA CORP /DE/ biological products, (no diagnostic substances) | 254.9K | 1.64% | 1.64% | $423.11M | Feb 3, 2026 | ▲ 242.8K |
WOODLINE PARTNERS LP biological products, (no diagnostic substances) | 165.6K | 1.07% | 1.07% | $274.96M | Nov 14, 2025 | — held |
WELLINGTON SHIELDS CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 69.5K | 44.84% | 44.84% | $115.43M | Nov 5, 2025 | ▼ 21.3K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 43.9K | 28.31% | 28.31% | $72.87M | Nov 13, 2025 | ▲ 4.7K |
TWO SIGMA INVESTMENTS, LP biological products, (no diagnostic substances) | 33.3K | 21.45% | 21.45% | $55.22M | Nov 14, 2025 | NEW |
WELLINGTON SHIELDS & CO., LLC biological products, (no diagnostic substances) | 30.1K | 19.41% | 19.41% | $49.95M | Nov 5, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 18.8K | 12.13% | 12.13% | $31.22M | Nov 12, 2025 | — held |
GROUND SWELL CAPITAL, LLC biological products, (no diagnostic substances) | 10.1K | 6.54% | 6.54% | $16.82M | Nov 6, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
3
Increased
+440.4K shares3
New Positions
first time holders2
Decreased
−22.3K shares5
Sold Out
fully exitedNet shares change (top 50)
+418.1K
+440.4K / −22.3K
Net new holders
-1
3 new / 5 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CASI insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
CASI Pharmaceuticals, Inc. (CASI) is primarily owned by institutional investors, who hold approximately 16.8% of total shares outstanding. Company insiders own approximately 77.94%, while retail and public investors account for the remaining 5.24%.
The largest institutional shareholder of CASI Pharmaceuticals, Inc. is VR ADVISER, LLC, holding approximately 987,259 shares — equal to 6.37% of outstanding shares — as of September 30, 2025.
A total of 21 institutional investors currently hold CASI stock, with a combined institutional value of approximately $4,327,257 as of the most recent 13F filing period.
Frequently asked questions
CASI ownershipCASI Pharmaceuticals, Inc. (CASI) is primarily owned by institutional investors, who hold approximately 16.8% of shares. The largest shareholder is VR ADVISER, LLC with a 6.37% stake. Company insiders hold 77.94%. Data sourced from SEC Form 13F as of September 30, 2025.